Organogenesis Holdings Inc. Q3 2025 Earnings Recap

ORGO Q3 2025 November 8, 2025

Organogenesis Holdings reported strong third quarter results for 2025, driven by a 31% increase in Advanced Wound Care product sales and strategic advancements in Medicare payment reforms, positioning the company favorably for future growth.

Earnings Per Share Miss

$0.18 vs $0.21 est.

-14.3% surprise

Revenue Miss

150864000 vs 172675000 est.

-12.6% surprise

Market Reaction

1-Day +0.0%

5-Day +10.3%

30-Day -11.37%

Key Takeaways

Q3 revenues exceeded guidance, with Advanced Wound Care sales up 31% year-over-year and Surgical & Sports Medicine sales climbing 25%.
The finalization of Medicare physician fee schedules marks a significant development, offering expanded access and potential for higher reimbursement for PMA products.
Progress on the ReNu program includes favorable clinical results, FDA RMAT designation, and an upcoming meeting scheduled for December to discuss the BLA submission.
The company maintained its competitive edge through strong brand equity and established customer relationships in the evolving skin substitute market.
Organogenesis is well-positioned to leverage changes in Medicare policy and drive innovation in regenerative medicine.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ORGO on AllInvestView.